



NEWS RELEASE

MDxHealth Appoints New Scientific Advisory Board

DURHAM, NC, and LIEGE, BELGIUM – March 24th, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has appointed a high profile Scientific Advisory Board (SAB) to support the Company's management in their new strategy. The SAB members will assist management in the development of current pipeline programs, as well as advise on new directions for the application of MDxHealth's technology platform.

"Each person joining our new Scientific Advisory Board is a pioneer in cancer molecular diagnostics, including prostate cancer, an indication where MDxHealth is particularly strong," said Dr. Jan Groen, Chief Executive Officer of MDxHealth. "Their long-standing experience and extensive networks will provide us with invaluable hands-on strategic support in the development of our existing programs and help us open up new avenues for the application of our DNA methylation platform."

The Scientific Advisory Board will consist of:

Jonathan I. Epstein, MD

Dr. Epstein is the Reinhard Professor of Urologic Pathology, Professor, Departments of Pathology, Urology and Oncology and Director of Surgical Pathology, Department of Pathology at the Johns Hopkins University School of Medicine. He is one of the acknowledged world experts in the field of urologic pathology. He is responsible for the largest genitourinary pathology fellowship program in the world, with four fellows per year. As Director of Genitourinary Pathology Consult Service he oversees approximately 16,000 genitourinary pathology consults received per year. His areas of particular interest include prostatic intraepithelial neoplasia; diagnosis of limited adenocarcinoma on needle biopsy; prediction of prostate cancer prognosis, and unusual subtypes of bladder carcinoma.

James G. Herman, MD

Dr. Herman is Professor of Oncology-Cancer Biology at the Oncology Center at Johns Hopkins Medical Institutions. His laboratory pioneered methylation-specific-PCR technology and continues to focus on epigenetic changes that pertain to development and progression of human cancers. Dr. Herman's publications have significantly advanced the fields of epigenetics and its impact on human cancer. Dr. Herman also has a clinical position in the Johns Hopkins Cancer Center. His applied research in the areas of pharmacogenomics and genomic instability have led to the development of diagnostic tests that could vastly improve clinical outcomes in patients with several types of cancer.

Gerrit A. Meijer, MD, PhD

Dr. Meijer is Professor of Pathology and chair of the Department of Pathology at the Free University Medical Center, in Amsterdam The Netherlands, co-chair of the Genomics Center, leader of the Master Oncology program, director of the Oncology Graduate School Amsterdam, and editor-in-chief of Cellular Oncology. Dr. Meijer is a pathologist with a special interest in cancer research, focusing on the gastrointestinal tract. He leads a research group that focuses on translational research in colorectal and gastric cancers. Current research topics include genomic and proteomic tumor profiling for stratifying patients for individually tailored therapies. Furthermore, genomic and proteomic profiling

of pre-malignant lesions is used for identification and validation of biomarkers for early cancer detection.

Eric M. Wallen, MD

Dr. Wallen is Associate Professor of Surgery in the Division of Urology at the University of North Carolina Medical Center at Chapel Hill, and focuses primarily on prostate cancer. Prior to 2003 he was Assistant Professor of Urology at Dartmouth Medical School in New Hampshire. Dr. Wallen obtained his Medical Doctor (MD) degree from the University of California, Los Angeles, School of Medicine and a Bachelor of Arts degree from Yale University in New Haven, Connecticut. He did his specialty training (internship and residency) in General Surgery and Urology at Stanford University Medical Center, Stanford, California. He is American Board Certified in the field of urology. Dr. Wallen is an expert in the cutting-edge technique of robotic, nerve-sparing prostatectomy surgery. Dr. Wallen has published widely in peer-reviewed journals and authored numerous medical book chapters. His in-depth knowledge of the diverse clinical settings of prostate cancer is gained from current patient management as well as involvement in cutting-edge research to improve disease diagnosis, treatment and prognosis.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University and Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Pfizer, and other industry leaders. More information can be found on the Company website: www.mdxhealth.com or on twitter at the following address : www.twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation